Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...

PLYMOUTH MEETING, PA [April 28, 2026] — The National Comprehensive Cancer Network ® (NCCN ®)—an alliance of leading cancer centers—has published a new book explaining the latest evidence and expert ...

Risk of death and cause of death 30 years after diagnosis as a proportion of 100 men. Grey figures indicate the proportion of men alive after 30 years, blue figures the proportion of men who died of ...

Men diagnosed with high-risk localized prostate cancer now have trial-level evidence that adding the drug apalutamide to ...

The National Comprehensive Cancer Network has announced that it has updated its practice guidelines for physicians to stress active surveillance rather than treatment for many men with low-risk ...

Dr. Rohan Garje shares the updated recommendations for the ASCO guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer. He discusses the systemic therapy ...

Patients who receive guideline-concordant treatment for nonmetastatic prostate cancer are more likely to die from other causes. Men with nonmetastatic prostate cancer (PCa) who receive treatment ...

CorePlus, Puerto Rico’s fully digital precision pathology and clinical laboratory, announced today the integration of the ...

To earn CME related to this news article, click here. February 25, 2009 — A new joint guideline produced by the American Society of Clinical Oncology (ASCO) and the American Urological Association ...

The answer depends on your individual risk for bone fracture and the type of exercise. For most men with early prostate cancer, it’s safe to engage in light or moderate exercise. Physical activity is ...